| Michael Garrison, MD | |
|
200 Old Country Rd, Suite 450, Mineola, NY 11501-4235 | |
| (516) 663-9500 | |
| (516) 663-4613 |
| Full Name | Michael Garrison |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 35 Years |
| Location | 200 Old Country Rd, Mineola, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003869447 | NPI | - | NPPES |
| 01573179 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 184395-1 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York University Langone Medical Center | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York University | 1355232422 | 4431 |
News Archive
Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.
The Bill & Melinda Gates Foundation announced this week "that it is accepting proposals for Round 8 of its Grand Challenges Explorations, a $100 million grant initiative to encourage innovation in global health and development research," according to a Gates Foundation press release.
As wind power generation becomes more important, experts in Australia are examining whether wind 'farm' turbine background noise in the environmental can affect sleep and wellbeing of nearby residents.
Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.
With the rise of many women delaying when they have a baby until they are older researchers are developing a test that can now tell a woman in her twenties how long she has left to start a family.
› Verified 3 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20081202000185 |
News Archive
Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.
The Bill & Melinda Gates Foundation announced this week "that it is accepting proposals for Round 8 of its Grand Challenges Explorations, a $100 million grant initiative to encourage innovation in global health and development research," according to a Gates Foundation press release.
As wind power generation becomes more important, experts in Australia are examining whether wind 'farm' turbine background noise in the environmental can affect sleep and wellbeing of nearby residents.
Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.
With the rise of many women delaying when they have a baby until they are older researchers are developing a test that can now tell a woman in her twenties how long she has left to start a family.
› Verified 3 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.
The Bill & Melinda Gates Foundation announced this week "that it is accepting proposals for Round 8 of its Grand Challenges Explorations, a $100 million grant initiative to encourage innovation in global health and development research," according to a Gates Foundation press release.
As wind power generation becomes more important, experts in Australia are examining whether wind 'farm' turbine background noise in the environmental can affect sleep and wellbeing of nearby residents.
Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.
With the rise of many women delaying when they have a baby until they are older researchers are developing a test that can now tell a woman in her twenties how long she has left to start a family.
› Verified 3 days ago
| Entity Name | Winthrop Community Medical Affiliates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457873077 PECOS PAC ID: 5698092385 Enrollment ID: O20150317001669 |
News Archive
Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.
The Bill & Melinda Gates Foundation announced this week "that it is accepting proposals for Round 8 of its Grand Challenges Explorations, a $100 million grant initiative to encourage innovation in global health and development research," according to a Gates Foundation press release.
As wind power generation becomes more important, experts in Australia are examining whether wind 'farm' turbine background noise in the environmental can affect sleep and wellbeing of nearby residents.
Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.
With the rise of many women delaying when they have a baby until they are older researchers are developing a test that can now tell a woman in her twenties how long she has left to start a family.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Garrison, MD 200 Old Country Rd, Suite 450, Mineola, NY 11501-4235 Ph: (516) 663-9500 | Michael Garrison, MD 200 Old Country Rd, Suite 450, Mineola, NY 11501-4235 Ph: (516) 663-9500 |
News Archive
Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.
The Bill & Melinda Gates Foundation announced this week "that it is accepting proposals for Round 8 of its Grand Challenges Explorations, a $100 million grant initiative to encourage innovation in global health and development research," according to a Gates Foundation press release.
As wind power generation becomes more important, experts in Australia are examining whether wind 'farm' turbine background noise in the environmental can affect sleep and wellbeing of nearby residents.
Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.
With the rise of many women delaying when they have a baby until they are older researchers are developing a test that can now tell a woman in her twenties how long she has left to start a family.
› Verified 3 days ago
Dr. Marlene Martins Lobato, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 173 Mineola Blvd, Suite 403, Mineola, NY 11501 Phone: 516-741-8891 Fax: 516-741-8829 | |
Dr. Anupama Ananda, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 190 Willis Ave, Suite 210, Mineola, NY 11501 Phone: 516-739-7290 Fax: 516-793-7291 | |
Mr. Jeffrey Liu, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 297 Mineola Blvd, Mineola, NY 11501 Phone: 516-294-1377 Fax: 516-294-5574 | |
Dr. Jonathan Shulman, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 259 1st St, Mineola, NY 11501 Phone: 516-663-2381 | |
John I Hogan, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 222 Station Plz N Ste 432, Mineola, NY 11501 Phone: 516-663-2507 | |
Dr. Anthony Massimillo, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 300 Old Country Rd Ste 31, Mineola, NY 11501 Phone: 516-294-9380 Fax: 516-294-5351 |